Overview Technical Risk & rank Results Accounts Filings Options Guidance & governance
Guidance tracker
What MANKIND guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 30 Oct 2026 | Mankind Pharma filed the transcript of its Q2 & H1 FY27 earnings conference call held on October 26, 2026. Management reported Q2 FY27 revenue of Rs 4,338 crores, up 17% year-on-year, and EBITDA of Rs 1,175 crores, up 27.2%, with EBITDA margin of 27.1% (up 210 bps). Management said PAT for Q2 FY27 rose 37.7%... NSE copy | No results filed since | ||
| 27 Oct 2026 | Mankind Pharma filed an investor presentation for an analyst/institutional investors' meet, in continuation of its October 22, 2026 intimation of the meet schedule. FY26 revenue was ₹14,278 Cr, with an 18.1% revenue CAGR over FY21–26; the company says it is #1 in prescription rank for 9 years and #4 in IPM by... NSE copy | No results filed since | ||
| 04 Aug 2026 | Mankind Pharma filed the transcript of its Q1 FY27 earnings conference call held on July 30, 2026. Management reported Q1 FY27 revenue from operations of INR4,031 crores, up 12.9% year-on-year, and reported EBITDA margin of 26.3% (up 250 bps); PAT rose 29.1% year-on-year to INR574 crores. Management said domestic... NSE copy | +39.1 % | +17.3 % | +8.2 % |
| 26 May 2026 | Mankind Pharma filed the transcript of its Q4 & FY26 investor conference call held on May 20, 2026. Q4 FY26 revenue from operations rose 11.8% year-on-year to INR3,443 crores; adjusted EBITDA margin was 27.1% and PAT grew 30.4% to INR559 crores (management). FY26 revenue rose 17.0% to INR14,278 crores with adjusted... NSE copy | +29.6 % | +12.9 % | -4.1 % |
| 09 Feb 2026 | Mankind Pharma filed the transcript of its Q3 and 9M FY26 investor conference call held on February 3, 2026. Management said Q3 FY26 revenue rose 11.5% year-on-year to INR3,567 crores, with adjusted EBITDA margin of 25.9%, and 9M FY26 revenue rose 18.7% to INR10,835 crores with adjusted EBITDA margin of 24.9%.... NSE copy | - | - | +3.7 % |
| 11 Nov 2025 | Mankind Pharma filed the transcript of its Q2 & H1 FY26 investor conference call held on November 6, 2025. Management reported Q2 FY26 revenue from operations up 21% year-on-year to INR3,697 crores with reported EBITDA margin of 25%; H1 FY26 revenue up 23% to INR7,268 crores with adjusted EBITDA margin of 24.4%.... NSE copy | +7.5 % | +10.4 % | -3.4 % |
| 06 Nov 2025 | Mankind Pharma filed its investor presentation on Q2 FY26 financial results (dated 6 November 2025). Consolidated revenue from operations rose 20.8% YoY to INR 3,697 crore in Q2 FY26; profit after tax fell 21.3% YoY to INR 520 crore; EBITDA was INR 924 crore (up 8.7% YoY). Domestic business revenue grew 14.5% YoY... NSE copy | +7.5 % | +10.4 % | -3.4 % |
| 06 Aug 2025 | Mankind Pharma filed the transcript of its Q1 FY26 earnings conference call held on August 1, 2025. Management reported Q1 FY26 revenue from operations of Rs 3,570 crores, up 24.5% year-on-year, with reported EBITDA of Rs 850 crores and an EBITDA margin of 23.8%; profit after tax was Rs 445 crores, down 17.4%... NSE copy | -21.7 % | +20.2 % | -2.0 % |
| 27 May 2025 | Mankind Pharma filed the transcript of its Q4 and FY25 investor conference call held on May 21, 2025. Management reported Q4 FY25 revenue from operations of INR3,079 crores (up 27.1% YoY) and adjusted EBITDA margin of 23.1%; FY25 revenue of INR12,207 crores (up 19%) and adjusted EBITDA margin of 25.9%. Management... NSE copy | -18.3 % | +23.4 % | -0.0 % |
| 30 Jan 2025 | Mankind Pharma filed the transcript of its Q3 and 9M FY25 investor conference call held on January 24, 2025. Management reported Q3 FY25 revenue up 24% year-on-year to INR3,230 crores, with adjusted EBITDA margin of 27.7% and organic growth of 11.2% year-on-year (domestic 8.4%, export 43%). For 9M FY25, revenue... NSE copy | -18.3 % | +23.4 % | -0.0 % |
Filings tagged as guidance, newest first (10 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 29 Oct 2026 | Credit rating | Mankind Pharma Limited filed intimation under Regulations 30 and 51 of the Listing Regulations about credit rating actions by CRISIL Ratings Limited, released October 29, 2026. CRISIL reaffirmed Non-Convertible Debentures of ₹400 crore and ₹2,100 crore at Crisil AA+/Stable. CRISIL withdrew the rating on... NSE copy |
| 26 Oct 2026 | Legal or regulatory | Mankind Pharma's board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, with limited review reports from S. R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co. The board approved a Scheme of Arrangement for amalgamation of wholly owned subsidiaries... NSE copy |
| 26 Oct 2026 | Legal or regulatory | Mankind Pharma's board on October 26, 2026 approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, with limited review reports from joint auditors S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co. The board approved a Scheme of Arrangement for amalgamation... NSE copy |
| 26 Oct 2026 | Legal or regulatory | Board of Mankind Pharma Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review reports from joint statutory auditors S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co. Board approved a Scheme of Arrangement for... NSE copy |
| 26 Aug 2026 | Legal or regulatory | Mankind Pharma's board, at its meeting on August 26, 2026, took note of approval by Bharat Serums and Vaccines Limited (BSVL), a material wholly owned subsidiary, to prepare for voluntary liquidation of BSVL. The Company holds 96% of BSVL directly and 4% is held by Appian Properties Private Limited, a wholly owned... NSE copy |
| 10 Aug 2026 | Management change | Board of Mankind Pharma approved the appointment of Mr. Anish Vanraj Bafna (DIN: 02925792) as an Additional Director, Non-Executive Independent Director, effective August 10, 2026. Appointment is for a term of 5 consecutive years, subject to approval of members. The Board approved a Postal Ballot Notice seeking... NSE copy |
| 30 Jul 2026 | Legal or regulatory | Mankind Pharma's board on July 30, 2026 approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a limited review report from joint statutory auditors S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co. The board also approved issuance of a corporate guarantee... NSE copy |
| 19 May 2026 | Legal or regulatory, Management change | Mankind Pharma's board on May 19, 2026 approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, with unmodified audit opinions (figures are in the annexure, not in the first pages). The board approved an additional investment of up to ₹500 crores in wholly owned subsidiary... NSE copy |
| 19 May 2026 | Legal or regulatory, Management change | Mankind Pharma's board on May 19, 2026 approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, with unmodified audit opinions; the pages shown do not give the revenue or profit figures. Board approved re-appointment of Satish Kumar Sharma as Whole-Time Director for 5... NSE copy |
| 12 May 2026 | Credit rating | Mankind Pharma Limited filed an intimation of credit ratings issued by ICRA Limited, dated May 12, 2026, at the Company's request. Fund based long-term/short-term limits of ₹1,250.00 crore: [ICRA]AA+ (Stable)/[ICRA]A1+, reaffirmed. Non-convertible debentures of ₹5,000.00 crore: [ICRA]AA+ (Stable), reaffirmed.... NSE copy |
| 22 Apr 2026 | Credit rating | Mankind Pharma Limited intimated that, at the company's request, CARE Ratings Limited has assigned credit ratings. Rated instrument: long-term/short-term bank facilities of ₹1,000.00 crore. Ratings assigned: CARE AA+; Stable (long-term) and CARE A1+ (short-term). The information will also be available on the... NSE copy |
| 24 Feb 2026 | Credit rating | Mankind Pharma Limited filed intimation under Regulations 30 and 51 of the Listing Regulations that ICRA Limited reaffirmed its credit ratings by letter dated February 24, 2026. Non-Convertible Debentures of ₹5,000 crore: rated AA+/Stable by ICRA, reaffirmed. Long-term/Short-term fund based limits of ₹1,250 crore:... NSE copy |
| 16 Jan 2026 | Credit rating | Mankind Pharma disclosed that ICRA Limited, at the company's request (letter dated January 16, 2026), withdrew the rating on its Commercial Paper of ₹1,500 crore, previously rated A1+. Other outstanding ICRA ratings cited: Non-Convertible Debentures of ₹5,000 crore rated AA+/Stable. Fund-based limits of ₹1,250... NSE copy |
| 13 Nov 2025 | Credit rating | Mankind Pharma Limited disclosed that ICRA Limited, at the company's request, withdrew its credit rating of A1+ on Commercial Paper of ₹3,500 crore by letter dated November 13, 2025. Other outstanding ICRA ratings: Non-Convertible Debentures of ₹5,000 crore rated AA+/Stable; Commercial Paper of ₹1,500 crore rated... NSE copy |
| 06 Nov 2025 | Legal or regulatory | Mankind Pharma Limited filed the outcome of its board meeting held on November 6, 2025, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The board meeting commenced at 3:00 p.m. (IST) and concluded at 4:00 p.m. (IST). The joint statutory... NSE copy |
| 29 Oct 2025 | Credit rating | Mankind Pharma Limited filed intimation under Regulations 30 and 51 of the Listing Regulations that CRISIL Ratings Limited, by letter dated October 29, 2025, withdrew or reaffirmed credit ratings on its instruments. Bank loan facilities of ₹1,250 crore: Crisil AA+/Stable, withdrawn. Non-convertible debentures of... NSE copy |
| 31 Jul 2025 | Legal or regulatory, Management change | Mankind Pharma Limited filed the outcome of its board meeting held on July 31, 2025, approving unaudited standalone and consolidated results for the quarter ended June 30, 2025. The board approved an interim dividend of ₹1 per equity share (100% on face value of ₹1), with August 8, 2025 fixed as the record date; it... NSE copy |
| 31 Jul 2025 | Legal or regulatory, Management change | Mankind Pharma's board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from joint statutory auditors (the results figures themselves are not in the pages provided). Board approved an interim dividend of ₹1 per equity share (100% on... NSE copy |
| 31 Jul 2025 | Legal or regulatory, Management change | Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with limited review reports from joint statutory auditors. Board approved interim dividend of ₹1 per equity share (100% on face value of ₹1), with record date Friday, August 8, 2025; payment within 30 days of... NSE copy |
| 31 Jul 2025 | Legal or regulatory, Management change | Mankind Pharma's board approved unaudited standalone and consolidated results for the quarter ended June 30, 2025, with the auditors' limited review report enclosed. The board approved an interim dividend of ₹1 per equity share (100% on face value of ₹1), with August 8, 2025 fixed as the record date; payment within... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (33 in all). A list of what was filed, not a judgement of the company.